Literature DB >> 20145382

Use of a tunnelled pleural catheter for the management of refractory hepatic hydrothorax: a new therapeutic option.

Pascale Mercky1, Lama Sakr, Laurent Heyries, Xavier Lagrange, José Sahel, Hervé Dutau.   

Abstract

Refractory hepatic hydrothorax poses a challenging therapeutic dilemma, as treatment options are limited. Herein, we describe the case of a 48-year-old lady with advanced cirrhosis and recurrent transudative pleural effusion despite a sodium-restricted diet, optimal diuretic therapy and transjugular intrahepatic portosystemic shunt. Given the patient's platelet and coagulation disorders, thoracoscopic pleurodesis was deemed unsafe. Instead, a tunneled pleural catheter (PleurX®) was inserted under local anesthesia. Pleural drainage was achieved at the time of catheter placement and subsequently according to the patient's symptoms. Symptomatic improvement and gradual decrease of drainage volumes were noted. Six months following placement of PleurX, methicillin-resistant Staphylococcus aureus cellulitis at the insertion site prompted catheter removal. No pleural effusion was seen on chest X-ray at that time. Subsequent follow-up revealed spontaneous pleurodesis, as no recurrence of pleural effusion was seen over a 6-month follow-up period. Very few data are available with regard to the use of indwelling pleural catheters for benign transudative pleural effusion, and more specifically hepatic hydrothorax. Herein, we present this novel potential indication of the indwelling pleural catheter and illustrate the successful clinical outcome.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2010        PMID: 20145382     DOI: 10.1159/000282493

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  9 in total

1.  Indwelling Pleural Catheters in Hepatic Hydrothorax: A Single-Center Series of Outcomes and Complications.

Authors:  Christopher Kniese; Khalil Diab; Marwan Ghabril; Gabriel Bosslet
Journal:  Chest       Date:  2018-07-07       Impact factor: 9.410

Review 2.  Hepatic Hydrothorax: An Updated Review on a Challenging Disease.

Authors:  Toufic Chaaban; Nadim Kanj; Imad Bou Akl
Journal:  Lung       Date:  2019-05-25       Impact factor: 2.584

3.  Mortality Following Catheter Drainage Versus Thoracentesis in Cirrhotic Patients with Pleural Effusion.

Authors:  Tsung-Hsing Hung; Chih-Wei Tseng; Chen-Chi Tsai; Yu-Hsi Hsieh; Kuo-Chih Tseng; Chih-Chun Tsai
Journal:  Dig Dis Sci       Date:  2017-01-27       Impact factor: 3.199

4.  Use of tunneled pleural catheters for the management of refractory hepatic hydrothorax.

Authors:  Raj Shah; Laura Succony; Shafick Gareeboo
Journal:  BMJ Case Rep       Date:  2011-08-17

5.  Indwelling Tunneled Pleural Catheters for Refractory Hepatic Hydrothorax in Patients With Cirrhosis: A Multicenter Study.

Authors:  Samira Shojaee; Najib Rahman; Kevin Haas; Ryan Kern; Michael Leise; Mohammed Alnijoumi; Carla Lamb; Adnan Majid; Jason Akulian; Fabien Maldonado; Hans Lee; Marwah Khalid; Todd Stravitz; Le Kang; Alexander Chen
Journal:  Chest       Date:  2018-08-29       Impact factor: 9.410

6.  Hepatic hydrothorax: indwelling catheter-related Acinetobacter radioresistens infection.

Authors:  Cristiano Silva Cruz; Valentina Tosatto; Paula Oliveira Nascimento; Rita Barata Moura
Journal:  BMJ Case Rep       Date:  2019-03-15

Review 7.  An Algorithm for Management After Transjugular Intrahepatic Portosystemic Shunt Placement According to Clinical Manifestations.

Authors:  Seung Kwon Kim; Bryan G Belikoff; Carlos J Guevara; Seong Jin Park
Journal:  Dig Dis Sci       Date:  2017-01-05       Impact factor: 3.199

8.  Complications of indwelling pleural catheter use and their management.

Authors:  Macy M S Lui; Rajesh Thomas; Y C Gary Lee
Journal:  BMJ Open Respir Res       Date:  2016-02-05

Review 9.  Experience with indwelling pleural catheters in the treatment of recurrent pleural effusions.

Authors:  Michel Chalhoub; Zulfiqar Ali; Louis Sasso; Michael Castellano
Journal:  Ther Adv Respir Dis       Date:  2016-09-21       Impact factor: 4.031

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.